This Article Full Text Full Text (PDF) CME: Take the course for this article: Circulation: September 16, 2008, Volume 118, Number 12 Correction Correction (v118,pe672) All Versions of this Article: 118/12/1225    most recent CIRCULATIONAHA.108.776757v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collet, J.-P. Articles by Montalescot, G. Search for Related Content PubMed PubMed Citation Articles by Collet, J.-P. Articles by Montalescot, G. Related Collections Cardiovascular Pharmacology Catheter-based coronary interventions: stents Acute coronary syndromes Antiplatelets Platelets Related Article

(Circulation. 2008;118:1225-1233.)
© 2008 American Heart Association, Inc.

Coronary Heart Disease

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study

Jean-Philippe Collet, MD, PhD; Johanne Silvain, MD; Antoine Landivier, MD; Marie-Laure Tanguy, PhD; Guillaume Cayla, MD; Anne Bellemain, MD; Nicolas Vignolles, BS; Sophie Gallier, BS; Farzin Beygui, MD, PhD; Ana Pena, PhD; Gilles Montalescot, MD, PhD

From the Institut de Cardiologie, Unité INSERM 856 (J.-P.C., J.S., A.L., G.C., A.B., N.V., S.G., F.B., A.P., G.M.), and Unité de Biostatistique (M.-L.T.), Pitié-Salpêtrière University Hospital (AP-HP), Paris, France.

Correspondence to Gilles Montalescot, MD, PhD, Bureau 236, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75013, Paris, France. E-mail gilles.montalescot{at}psl.aphp.fr

Received February 29, 2008; accepted July 2, 2008.

Background— Clopidogrel loading has mostly been studied in clopidogrel-naïve patients. Whether clopidogrel-treated patients readmitted for an acute coronary syndrome or percutaneous coronary intervention can benefit from a new load of clopidogrel and at what dose remain unknown. Our aim was to evaluate the impact of 3 different strategies of administration of a loading dose of 900 mg clopidogrel in patients already treated with a maintenance dose of 75 mg clopidogrel for at least 7 days on residual platelet aggregation.

Methods and Results— Patients treated long term by clopidogrel 75 mg/d were assigned to receive a first loading dose of 300, 600, or 900 mg clopidogrel and 4 hours later a second loading dose of 600, 300, or 0 mg, respectively, to achieve a total loading dose of 900 mg in all patients. Platelet aggregation was evaluated at baseline, at 4 hours after the initial load (and before second load), and at 24 hours using light transmission aggregometry with 20 µmol ADP and the point-of-care assay VerifyNow P2Y₁₂. The primary objective of the study was to evaluate the inhibition (relative change) of residual platelet aggregation (percentage of IRPA) between 600- and 900-mg first loading at 4 hours. IRPA at 24 hours also was evaluated as a secondary objective, as well as the rate of suboptimal response at 4 hours defined as IRPA <10%. We included 166 consecutive patients with acute coronary syndromes (n=80, 48%) or stable coronary artery disease (n=86, 52%). Baseline characteristics were similar in the 3 dose groups. A significant stepwise increase was found in percentage IRPA assessed at 4 hours in patients initially assigned to 300 versus 600 versus 900 mg (30.7% versus 40.3% versus 64.0%, respectively; P=0.0024). The difference in percentage IRPA at 4 hours was not significant between 300 and 600 mg but was significant between 600 and 900 mg and between 300 and 900 mg. Percentage IRPA assessed at 24 hours when all patients had received 900 mg did not differ between the 3 loading regimens. The rates of suboptimal response (IRPA <10% at 4 hours) were 23.6%, 20.4%, and 5.3% with 300, 600, and 900 mg, respectively (P=0.02 for all).

Conclusions— In patients treated long term with 75 mg clopidogrel, a new loading dose of 900 mg improves IRPA and reduces poor and/or slow response to clopidogrel significantly more than that obtained with 300 or 600 mg.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 1217-1218. [Extract] [Full Text]

This article has been cited by other articles:

				L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes N. Engl. J. Med., September 10, 2009; 361(11): 1045 - 1057. [Abstract] [Full Text] [PDF]

				J.-P. Collet and G. Montalescot Review: Platelet Function Testing and Implications for Clinical Practice Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2009; 14(3): 157 - 169. [Abstract] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				A. Pena, J.-P. Collet, J.-S. Hulot, J. Silvain, O. Barthelemy, F. Beygui, C. Funck-Brentano, and G. Montalescot Can We Override Clopidogrel Resistance? Circulation, June 2, 2009; 119(21): 2854 - 2857. [Full Text] [PDF]

				D. O. Williams and J. D. Abbott What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax? Circulation, September 16, 2008; 118(12): 1219 - 1222. [Full Text] [PDF]